Hypertriglyceridemia in combination antiretroviral-treated HIV-positive individuals: potential impact on HIV sensory polyneuropathy
- PMID: 21150557
- PMCID: PMC3729045
- DOI: 10.1097/QAD.0b013e328341dd68
Hypertriglyceridemia in combination antiretroviral-treated HIV-positive individuals: potential impact on HIV sensory polyneuropathy
Abstract
Objective: in HIV populations that are aging due to improved longevity with combination antiretroviral therapy (CART), both hypertriglyceridemia (hTRG) and sensory neuropathy have become increasingly common. Sensory neuropathy is associated with substantial long-term disability and frequently requires management with analgesics. Elevated serum triglycerides (TRGs) are associated with an increased risk for sensory neuropathy in diabetes mellitus. However, the contribution of hTRG to sensory neuropathy in HIV has not been carefully evaluated.
Design: prospective, comparative, single-center, cross-sectional cohort study.
Methods: clinical correlates of sensory neuropathy were assessed in HIV-positive and HIV-negative participants. HIV-sensory neuropathy was defined as one or more clinical signs of reduced distal sensation or ankle reflexes; symptoms were distal leg and foot pain, parasthesias or numbness. TRG levels were assessed along with concomitant metabolic and other risk factors including glucose, lipids, age, height, current and nadir CD4, and past or current use of protease inhibitors, dideoxynucleoside antiretrovirals (d-drugs), and statins in univariable and multivariable logistic regression.
Results: of 436 HIV patients (median age 52 years; 75% on CART), 27% had sensory neuropathy; 48% were symptomatic. TRG levels were significantly higher in HIV-positive than HIV-negative individuals (mean ± SD, 245 ± 242 versus 160 ± 97 mg/dl; P < 0.001). Among HIV-positive patients, those with TRG levels in the highest tertile (≥ 244 mg/dl) were more likely to have sensory neuropathy than those in the lowest tertile (reference, ≤ 142 mg/dl) after adjusting for concurrent predictors (adjusted odds ratio 2.7, 95% confidence interval 1.4-5.5).
Conclusions: elevated triglyceride levels increased the risk for HIV-sensory neuropathy in HIV-positive individuals independently of other known risk factors.
2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Similar articles
-
Peripheral neuropathy in HIV: prevalence and risk factors.AIDS. 2011 Apr 24;25(7):919-28. doi: 10.1097/QAD.0b013e328345889d. AIDS. 2011. PMID: 21330902 Free PMC article. Clinical Trial.
-
Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study.Arch Neurol. 2010 May;67(5):552-8. doi: 10.1001/archneurol.2010.76. Arch Neurol. 2010. PMID: 20457954 Free PMC article.
-
Role of metabolic syndrome components in HIV-associated sensory neuropathy.AIDS. 2009 Nov 13;23(17):2317-22. doi: 10.1097/QAD.0b013e328332204e. AIDS. 2009. PMID: 19823068 Free PMC article.
-
Diagnosis and management of HIV-associated neuropathy.Neurol Clin. 2008 Aug;26(3):821-32, x. doi: 10.1016/j.ncl.2008.04.001. Neurol Clin. 2008. PMID: 18657728 Review.
-
Recent advances in HIV neuropathy.Curr Opin Neurol. 2006 Oct;19(5):446-50. doi: 10.1097/01.wco.0000245366.59446.57. Curr Opin Neurol. 2006. PMID: 16969153 Review.
Cited by
-
HIV peripheral neuropathy and foot care management: a review of assessment and relevant guidelines.Am J Nurs. 2013 Dec;113(12):34-40; quiz 41. doi: 10.1097/01.NAJ.0000438867.67777.69. Am J Nurs. 2013. PMID: 24247663 Free PMC article. Review.
-
Sensory neuropathy and metabolic risk factors in human immune deficiency virus infected South Africans receiving protease inhibitors.AIDS Res Ther. 2015 Sep 23;12:30. doi: 10.1186/s12981-015-0073-8. eCollection 2015. AIDS Res Ther. 2015. PMID: 26401157 Free PMC article.
-
Predictors of new-onset distal neuropathic pain in HIV-infected individuals in the era of combination antiretroviral therapy.Pain. 2015 Apr;156(4):731-739. doi: 10.1097/01.j.pain.0000461252.75089.bf. Pain. 2015. PMID: 25659067 Free PMC article.
-
Peripheral neuropathy in HIV: prevalence and risk factors.AIDS. 2011 Apr 24;25(7):919-28. doi: 10.1097/QAD.0b013e328345889d. AIDS. 2011. PMID: 21330902 Free PMC article. Clinical Trial.
-
Prevalent neuropathy in a cohort of HIV-infected Kenyan sex workers using antiretroviral drugs.Pan Afr Med J. 2016 Sep 20;25:14. doi: 10.11604/pamj.2016.25.14.9699. eCollection 2016. Pan Afr Med J. 2016. PMID: 28154706 Free PMC article.
References
-
- Ellis RJ RD, Clifford DB, McArthur JC, Simpson D, Alexander T, Gelman BB, Vaida F, et al. the CHARTER Study Group Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: The CHARTER Study. Arch Neurol. 2010;67 - PMC - PubMed
-
- Bacellar H, Munoz A, Miller EN, Cohen BA, Besley D, Selnes OA, et al. Temporal trends in the incidence of HIV-1-related neurologic diseases: multicenter AIDS Cohort Study, 1985–1992. Neurology. 1994;44:1892–1900. - PubMed
-
- Tagliati M, Grinnell J, Godbold J, Simpson DM. Peripheral nerve function in HIV infection: clinical, electrophysiologic, and laboratory findings. Arch Neurol. 1999;56:84–89. - PubMed
-
- Childs EA, Lyles RH, Selnes OA, Chen B, Miller EN, Cohen BA, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology. 1999;52:607–613. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous